Robert Glickenberger, MD
Gastroenterology · Springfield, ILNPI 1407966690
Payments from drug & device makers
Across 671 payments — averaging $19.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Johnson & Johnson$1K
- Takeda Pharmaceuticals U.S.A., Inc.$616
- Gilead$540
- Phathom Pharmaceuticals, Inc.$538
- plus $4K from 22 others
What the payments were for
- Food & beverage$13,00097%
- Education$2452%
- Gifts$1071%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 249 | $5,045 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 101 | $1,671 |
| Johnson & Johnson | 104 | $1,394 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $616 |
| Gilead | 16 | $540 |
| Phathom Pharmaceuticals, Inc. | 24 | $538 |
| Intercept Pharmaceuticals, Inc. | 18 | $505 |
| Braintree Laboratories, Inc. | 19 | $349 |
| Ardelyx, Inc. | 14 | $313 |
| Ironwood Pharmaceuticals, Inc | 19 | $297 |
| Pfizer | 9 | $279 |
| Aimmune Therapeutics, Inc. | 12 | $266 |
| Daiichi Sankyo Inc. | 9 | $258 |
| Nestle Healthcare Nutrition Inc. | 13 | $234 |
| Bristol Myers Squibb | 11 | $227 |
| Janssen Scientific Affairs, LLC | 2 | $155 |
| Merck | 4 | $133 |
| Intuitive Surgical | 1 | $126 |
| Redhill Biopharma Inc. | 1 | $88 |
| Ferring Pharmaceuticals Inc. | 4 | $86 |
| Ipsen Biopharmaceuticals, Inc | 2 | $48 |
| Enterra Medical, Inc. | 1 | $38 |
| Shire North American Group Inc | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $33 |
| Madrigal Pharmaceuticals | 1 | $33 |
| Olympus America Inc. | 1 | $18 |
| Medtronic | 1 | $16 |
| Organon | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Skyrizi$259
- OCALIVA$222
- Epclusa$220
- Da Vinci Surgical System$126
- VELSIPITY$123
- VOQUEZNA$120
- Entyvio$107
- SUPREP BOWEL PREP$107
- INJECTAFER$106
- Mavyret$100
How this compares
$13,352 in reported general payments places this provider in the 80th percentile of 787 gastroenterology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 75 | $298,236 |
| ZenpepLipase/Protease/Amylase | 39 | $218,080 |
| Humira(Cf) PenAdalimumab | 19 | $182,301 |
| OcalivaObeticholic Acid | 13 | $122,181 |
| XifaxanRifaximin | 32 | $99,704 |
| LinzessLinaclotide | 77 | $81,155 |
| RinvoqUpadacitinib | 11 | $71,564 |
| VemlidyTenofovir Alafenamide | 12 | $16,121 |
| TrulancePlecanatide | 17 | $15,308 |
| Dicyclomine Hcl | 381 | $14,336 |
| Dexlansoprazole DrDexlansoprazole | 42 | $9,123 |
| Famotidine | 364 | $8,192 |
| Colestipol Hcl | 99 | $7,673 |
| Mesalamine | 25 | $7,281 |
| Ursodiol | 23 | $7,046 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Rinvoq | $5,045 | $450,955163 claims |
| Aimmune Therapeutics, Inc.Zenpep | $266 | $218,08039 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $505 | $122,18113 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $1,671 | $115,01249 claims |
| GileadVemlidy | $540 | $16,12112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 787 gastroenterology providers in Illinois.
Other gastroenterology in Springfield
- Dmitry ShusterSpringfield$967K
- Kamran AyubOak Lawn$4.3M
- David RubinChicago$3.6M
- Jonathan RosenbergGurnee$3.1M
- Stephen HanauerChicago$2.9M
- Parambir DulaiChicago$2.2M
- Charles BerkelhammerOak Lawn$1.9M
- Ikuo HiranoChicago$1.8M
- Manish BhuvaLake Barrington$1.7M
- Steven FlammChicago$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.